Case Report
Accepted on 22 Aug 2025
Three cases with allogeneic CIK therapy against solid tumors
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1658864
- 218 views
Type at least 3 characters
8,365 articles
Original Research
Accepted on 22 Aug 2025
Pan-Cancer Analysis of PIEZO1: A Promising Biomarker for Diagnosis, Prognosis, and Targeted Therapies
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1625734
- 201 views
Original Research
Accepted on 22 Aug 2025
Exosomal FABP5 Drives HCC Progression via Macrophage Lipid Metabolism and Immune Microenvironment Remodeling
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1644645
- 123 views
Review
Accepted on 22 Aug 2025
Tumor-infiltrating lymphocytes and tumor-associated macrophages in cancer immunoediting: a targetable therapeutic axis
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1655176
- 117 views
Review
Accepted on 22 Aug 2025
Multi-Omics Analysis of the Tumor Microenvironment After Metastasis: Advancing Toward Personalized Immunotherapy and Molecular Targeted Strategies
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1648987
Review
Accepted on 22 Aug 2025
Mechanisms, Advances, and Challenges of Immunotherapy in Gastric Cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1639487
- 115 views
Original Research
Accepted on 22 Aug 2025
Extracellular vesicles from prostate tumors reshape the pre-metastatic bone environment in an mTOR/RAB1A-dependent manner
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1605494
Original Research
Published on 22 Aug 2025
The impact of immunotherapy on the prognosis of small cell carcinoma of the esophagus: a propensity score-matched analysis of a retrospective study
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1634834
- 397 views
Original Research
Published on 22 Aug 2025
Exploring research trends in cancer immunotherapy via single-cell technologies: a scientometric perspective
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1640224
- 595 views
Correction
Published on 22 Aug 2025
Correction: Case Report: CAR-T therapy for primary cerebellar ALK-negative anaplastic large cell lymphoma
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1674954
- 381 views
Original Research
Published on 22 Aug 2025
Verteporfin inhibits the cGAS-STING pathway and improves the tumor microenvironment during cisplatin treatment in hepatocellular carcinoma
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1658042
- 311 views
Original Research
Published on 22 Aug 2025
Case Report: Abscopal effect and long-term survival in a PD-L1 negative NSCLC patient treated with radiotherapy and immuno-chemotherapy
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1613974
- 364 views
Original Research
Published on 22 Aug 2025
Expressed mutated genes in Sezary syndrome and their potential prognostic value in patients treated with extracorporeal photopheresis
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1589467
- 429 views
Original Research
Published on 22 Aug 2025
Tertiary lymphoid structures correlate with the therapeutic efficacy and prognosis of resectable esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy plus immunotherapy
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1616247
- 322 views
Case Report
Accepted on 21 Aug 2025
Successful surgical management of unresectable stage IIIB LSCC following neoadjuvant chemotherapy combined with toripalimab: A case report
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1651208
- 139 views
Original Research
Accepted on 21 Aug 2025
Arsenic sulfide enhances the therapeutic effect of hepatocellular carcinoma immunotherapy through STAT3-THBS1/CD47 pathway
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1612318
- 131 views